Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Mr Harvey White,
Analyses from long-term follow up of the landmark ACUITY trial presented today demonstrate that in moderate and high risk acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), treatment with bivalirudin alone resulted in significantly less bleeding at 30 days and comparable composite ischemia and mortality at 1 year than heparin (either unfractionated or enoxaparin) plus a glycoprotein IIb/IIIa inhibitor regardless of patient risk. The mortality results observed at 1 year with bivalirudin monotherapy were not dependent on the timing of clopidogrel administration.
Switching to bivalirudin monotherapy from prior treatment with unfractionated heparin or enoxaparin was also proven to be safe and effective, enabling patients to achieve the approximate 50% reduction in major bleeding while preserving similar protection from adverse ischemic outcome and death at 1 year.
PCI patients experiencing a non-CABG major bleed had a significantly longer length of hospital stay, 5.0 days vs 3.0 days (p<0.0001), compared with those that did not bleed. Further, a strong association was observed between early bleeding events and late mortality in ACS patients undergoing PCI.
These results suggest bivalirudin monotherapy should be the preferred adjunctive antithrombotic strategy in moderate and high risk ACS patients undergoing PCI and add to the evidence on the relationship between early bleeding and long-term outcome.
Clinical Trial Update I
© 2017 European Society of Cardiology. All rights reserved